Paul A Sobotka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11966490/publications.pdf

Version: 2024-02-01

57758 64796 13,602 83 44 79 citations h-index g-index papers 83 83 83 5548 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2) Tj ETQq1	1.0.78431	14 rgBT /0vi 2,002
2	Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet, The, 2009, 373, 1275-1281.	13.7	1,918
3	Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2007, 49, 675-683.	2.8	978
4	Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension. New England Journal of Medicine, 2009, 361, 932-934.	27.0	702
5	Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet, The, 2014, 383, 622-629.	13.7	556
6	Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension. Circulation, 2011, 123, 1940-1946.	1.6	541
7	Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal, 2015, 36, 219-227.	2.2	458
8	Effects of Renal Sympathetic Denervation on Blood Pressure, Sleep Apnea Course, and Glycemic Control in Patients With Resistant Hypertension and Sleep Apnea. Hypertension, 2011, 58, 559-565.	2.7	427
9	Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension. Circulation, 2012, 126, 2976-2982.	1.6	420
10	Ultrafiltration Versus Usual Care for Hospitalized Patients With Heart Failure. Journal of the American College of Cardiology, 2005, 46, 2043-2046.	2.8	375
11	Renal Denervation in Moderate to Severe CKD. Journal of the American Society of Nephrology: JASN, 2012, 23, 1250-1257.	6.1	322
12	Catheterâ€Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTNâ€3 Trial. Clinical Cardiology, 2012, 35, 528-535.	1.8	278
13	First-in-man safety evaluation of renal denervation for chronic systolic heart failure: Primary outcome from REACH-Pilot study. International Journal of Cardiology, 2013, 162, 189-192.	1.7	274
14	Sympathetically Mediated Changes in Capacitance. Circulation: Heart Failure, 2011, 4, 669-675.	3.9	251
15	Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension. Circulation, 2013, 128, 132-140.	1.6	240
16	The Carotid Body as a Therapeutic Target for the Treatment of Sympathetically Mediated Diseases. Hypertension, 2013, 61, 5-13.	2.7	232
17	Renal Denervation as a Therapeutic Approach for Hypertension. Hypertension, 2009, 54, 1195-1201.	2.7	220
18	Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clinical Research in Cardiology, 2012, 101, 63-67.	3.3	216

#	Article	IF	CITATIONS
19	The carotid body as a putative therapeutic target for the treatment of neurogenic hypertension. Nature Communications, 2013, 4, 2395.	12.8	204
20	Hypertension is critically dependent on the carotid body input in the spontaneously hypertensive rat. Journal of Physiology, 2012, 590, 4269-4277.	2.9	188
21	Sympatho-renal axis in chronic disease. Clinical Research in Cardiology, 2011, 100, 1049-1057.	3.3	155
22	Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet, The, 2015, 385, 1634-1641.	13.7	155
23	Cardiorespiratory Response to Exercise After Renal Sympathetic Denervation in Patients With Resistant Hypertension. Journal of the American College of Cardiology, 2011, 58, 1176-1182.	2.8	142
24	Ultrafiltration is Associated With Fewer Rehospitalizations than Continuous Diuretic Infusion in Patients With Decompensated Heart Failure: Results From UNLOAD. Journal of Cardiac Failure, 2010, 16, 277-284.	1.7	130
25	Renal denervation: a potential new treatment modality for polycystic ovary syndrome?. Journal of Hypertension, 2011, 29, 991-996.	0.5	124
26	International Expert Consensus Statement. Journal of the American College of Cardiology, 2013, 62, 2031-2045.	2.8	124
27	Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. International Journal of Cardiology, 2013, 168, 2214-2220.	1.7	122
28	Unilateral Carotid Body Resection inÂResistant Hypertension. JACC Basic To Translational Science, 2016, 1, 313-324.	4.1	118
29	Carotid body resection for sympathetic modulation in systolic heart failure: results from firstâ€inâ€man study. European Journal of Heart Failure, 2017, 19, 391-400.	7.1	97
30	Renal Denervation in Moderate Treatment-Resistant Hypertension. Journal of the American College of Cardiology, 2013, 62, 1880-1886.	2.8	93
31	The Role of Renal Denervation in the Treatment of Heart Failure. Current Cardiology Reports, 2012, 14, 285-292.	2.9	83
32	Carotid body removal for treatment of chronic systolic heart failure. International Journal of Cardiology, 2013, 168, 2506-2509.	1.7	83
33	Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea. Hypertension, 2018, 72, 381-390.	2.7	73
34	Renal Denervation for Hypertension. JACC: Cardiovascular Interventions, 2012, 5, 249-258.	2.9	70
35	Expired Hydrocarbons in Patients with Acute Myocardial Infarction. Free Radical Research, 1995, 23, 117-122.	3.3	68
36	Renal nerve ablation reduces augmentation index in patients with resistant hypertension. Journal of Hypertension, 2013, 31, 1893-1900.	0.5	66

#	Article	lF	Citations
37	Loop Diuretics Can Cause Clinical Natriuretic Failure: A Prescription for Volume Expansion. Congestive Heart Failure, 2009, 15, 1-4.	2.0	63
38	Renal Denervation and Hypertension. American Journal of Hypertension, 2011, 24, 635-642.	2.0	63
39	Revelations About Carotid Body Function Through its Pathological Role in Resistant Hypertension. Current Hypertension Reports, 2013, 15, 273-280.	3.5	62
40	Dissociation between blood pressure and heart rate response to hypoxia after bilateral carotid body removal in men with systolic heart failure. Experimental Physiology, 2014, 99, 552-561.	2.0	52
41	Vascular and Renal Hemodynamic Changes after Renal Denervation. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1195-1201.	4.5	51
42	Arteriovenous Anastomosis. Hypertension, 2014, 64, 6-12.	2.7	49
43	Breath pentane and plasma lipid peroxides in ischemic heart disease. Free Radical Biology and Medicine, 1995, 19, 679-684.	2.9	46
44	Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension. Hypertension, 2017, 70, 1099-1105.	2.7	44
45	Renal Denervation in Human Hypertension: Mechanisms, Current Findings, and Future Prospects. Current Hypertension Reports, 2012, 14, 247-253.	3.5	43
46	Clinical Predictors and Hemodynamic Consequences of Elevated Peripheral Chemosensitivity in Optimally Treated Men With Chronic Systolic Heart Failure. Journal of Cardiac Failure, 2013, 19, 408-415.	1.7	43
47	Renal Sympathetic Nerve Ablation: The New Frontier in the Treatment of Hypertension. Current Hypertension Reports, 2010, 12, 39-46.	3.5	41
48	Myocellular and Interstitial Edema and Circulating Volume Expansion as a Cause of Morbidity and Mortality in Heart Failure. Journal of Cardiac Failure, 2007, 13, 133-136.	1.7	37
49	Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations. European Journal of Heart Failure, 2021, 23, 1076-1084.	7.1	37
50	Renal Denervation in a Hypertensive Patient With Endâ€Stage Renal Disease and Small Arteries: A Direction for Future Research. Journal of Clinical Hypertension, 2012, 14, 799-801.	2.0	35
51	Interventional procedures and future drug therapy for hypertension. European Heart Journal, 2017, 38, ehw303.	2.2	34
52	Extracardiac Abnormalities of Preload Reserve. Circulation: Heart Failure, 2021, 14, e007308.	3.9	33
53	The ROX coupler: Creation of a fixed iliac arteriovenous anastomosis for the treatment of uncontrolled systemic arterial hypertension, exploiting the physical properties of the arterial vasculature. Catheterization and Cardiovascular Interventions, 2015, 85, 880-886.	1.7	28
54	Selective vs. Global Renal Denervation: a Case for Less Is More. Current Hypertension Reports, 2018, 20, 37.	3.5	27

#	Article	IF	Citations
55	Chemohypersensitivity and Autonomic Modulation of Venous Capacitance in the Pathophysiology of Acute Decompensated Heart Failure. Current Heart Failure Reports, 2013, 10, 139-146.	3.3	24
56	Renal Nerves in the Maintenance of Hypertension: A Potential Therapeutic Target. Current Hypertension Reports, 2010, 12, 196-204.	3.5	23
57	The Sympathorenal Axis in Hypertension and Heart Failure. Journal of Cardiac Failure, 2010, 16, 369-373.	1.7	23
58	Central Iliac Arteriovenous Anastomosis for Hypertension: Targeting Mechanical Aspects of the Circulation. Current Hypertension Reports, 2015, 17, 585.	3.5	23
59	Prediction of readmissions and mortality in patients with heart failure: lessons from the IMPEDANCEâ€HF extended trial. ESC Heart Failure, 2018, 5, 788-799.	3.1	23
60	Fluid Re-Distribution Rather Than Accumulation Causes Most Cases of Decompensated Heart Failure. Journal of the American College of Cardiology, 2013, 62, 165-166.	2.8	22
61	Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension. Journal of the American Heart Association, 2016, 5, .	3.7	22
62	Meta-Analysis of the Effect of Renal Denervation on Blood Pressure and Pulse Pressure in Patients With Resistant Systemic Hypertension. American Journal of Cardiology, 2014, 114, 856-861.	1.6	21
63	Catheter-Based Renal Denervation for Hypertension. Current Hypertension Reports, 2018, 20, 93.	3.5	16
64	Enhanced Sodium Extraction with Ultrafiltration Compared to Intravenous Diuretics. Journal of Cardiac Failure, 2006, 12, S114.	1.7	14
65	A Practical Guide for Ultrafiltration in Acute Decompensated Heart Failure. Congestive Heart Failure, 2008, 14, 83-88.	2.0	14
66	Recent advances in the treatment of hypertension. Expert Review of Cardiovascular Therapy, 2011, 9, 729-744.	1.5	14
67	Antihypertensive Effects of a Central Arteriovenous Anastomosis Are Mediated Through Profound Reduction in Systemic Vascular Resistance. Circulation: Cardiovascular Interventions, 2016, 9, e004012.	3.9	10
68	Central arteriovenous anastomosis to treat resistant hypertension. Current Opinion in Nephrology and Hypertension, 2018, 27, 8-15.	2.0	10
69	Renal Denervation for Patients With Heart Failure. Circulation: Heart Failure, 2021, 14, e008301.	3.9	10
70	Does Renal Artery Supply Indicate Treatment Success of Renal Denervation?. CardioVascular and Interventional Radiology, 2013, 36, 987-991.	2.0	7
71	Ready for a Marathon, Not a Sprint. Journal of the American College of Cardiology, 2013, 62, 2131-2133.	2.8	7
72	Sham trials: benefits and risks for cardiovascular research and patients. Lancet, The, 2019, 393, 2104-2106.	13.7	7

#	Article	IF	CITATIONS
73	Percutaneous Creation of a Central Iliac Arteriovenous Anastomosis for the Treatment of Arterial Hypertension. Current Hypertension Reports, 2018, 20, 18.	3.5	5
74	The Improved Outcomes Following Ultrafiltration Versus Intravenous Diuretics in UNLOAD Are Not Solely Due to Increased Weight Loss in the Ultrafiltration Group. Journal of Cardiac Failure, 2007, 13, S188-S189.	1.7	4
75	Correlation of Quantitated Intravascular Volume with Blood Pressure in Patients with Systemic Hypertension. Journal of Cardiovascular Translational Research, 2020, 13, 528-530.	2.4	4
76	Response to Role of the Carotid Body in Obesity-Related Sympathoactivation. Hypertension, 2013, 61, e58.	2.7	2
77	The Thrill of Success: Central Arterial-Venous Anastomosis for Hypertension. Current Hypertension Reports, 2014, 16, 497.	3.5	2
78	Efficiently Doing the Wrong Thing. Journal of the American College of Cardiology, 2012, 60, 1713.	2.8	1
79	Central arteriovenous anastomosis and hypertension – Authors' reply. Lancet, The, 2015, 386, 1821-1822.	13.7	1
80	Response to Letter Regarding Article, "Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Study― Circulation, 2011, 124, .	1.6	0
81	Response to Letter Regarding Article, "Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension― Circulation, 2014, 129, e500-1.	1.6	0
82	Devices for Hypertension., 2013,, 230-235.		0
83	The Endpoint on Measuring the Clinical Effects of Renal Denervation: What Are the Best Surrogates. , 2015, , 25-43.		O